High fatality rate of Epstein-Barr virus-associated lymphoproliferative disorder occurring after bone marrow transplantation with rabbit antithymocyte globulin conditioning regimens
- PMID: 16000501
- PMCID: PMC1169101
- DOI: 10.1128/JCM.43.7.3540-3543.2005
High fatality rate of Epstein-Barr virus-associated lymphoproliferative disorder occurring after bone marrow transplantation with rabbit antithymocyte globulin conditioning regimens
Abstract
Epstein-Barr virus (EBV)-associated lymphoproliferative disorder (EBV-LPD) following bone marrow transplantation can be fatal. The major risk factors for the development of EBV-LPD are ex vivo T-cell depletion or in vivo T-cell depletion with either antithymocyte globulin (ATG) or monoclonal anti-T-cell antibodies. Between March 1999 and January 2001, a total of 23 transplants with ATG of equine source (20 transplants) and ATG of rabbit source (3 transplants) used as part of the preparatory regimen were performed at the Barbara Ann Karmanos Cancer Institute in Detroit, Mich. The three patients who received rabbit ATG developed EBV-LPD between 60 and 90 days following bone marrow transplantation. However, there were no cases of EBV-LPD in the equine group. Treatment given in these cases consisted of tapering immunosuppression, antiviral therapy, unprocessed donor lymphocyte infusion, mobilized peripheral blood progenitor cell rescue infusion (one patient), and chemotherapy (one patient). All three patients died of complications from EBV-LPD. The association of rabbit ATG with the development of EBV-LPD suggests that patients receiving rabbit ATG as part of their preparatory regimens require close monitoring of the EBV viral load and possible early intervention with antiviral therapy.
Figures



Similar articles
-
Epstein-Barr virus-associated B cell lymphoproliferative disorder following mismatched related T cell-depleted bone marrow transplantation.Bone Marrow Transplant. 2001 Dec;28(12):1117-23. doi: 10.1038/sj.bmt.1703311. Bone Marrow Transplant. 2001. PMID: 11803352
-
Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients.Curr Opin Hematol. 2008 Nov;15(6):576-85. doi: 10.1097/MOH.0b013e328311f438. Curr Opin Hematol. 2008. PMID: 18832928 Review.
-
Unrelated bone marrow transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease.Bone Marrow Transplant. 2003 Jan;31(2):105-11. doi: 10.1038/sj.bmt.1703796. Bone Marrow Transplant. 2003. PMID: 12621491
-
Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease.J Med Virol. 2008 Mar;80(3):441-54. doi: 10.1002/jmv.21096. J Med Virol. 2008. PMID: 18205222
-
Immune-cell treatment of Epstein--Barr-virus-associated lymphoproliferative disorders.Best Pract Res Clin Haematol. 2006;19(4):839-47. doi: 10.1016/j.beha.2006.06.003. Best Pract Res Clin Haematol. 2006. PMID: 16997187 Review.
Cited by
-
Epstein-Barr virus-related lymphoproliferative disorder induced by equine anti-thymocyte globulin therapy.Med Oncol. 2011 Dec;28(4):1604-8. doi: 10.1007/s12032-010-9635-8. Epub 2010 Aug 3. Med Oncol. 2011. PMID: 20680523
-
Simultaneous quantification of Epstein-Barr virus, cytomegalovirus, and human herpesvirus 6 DNA in samples from transplant recipients by multiplex real-time PCR assay.J Clin Microbiol. 2007 May;45(5):1426-32. doi: 10.1128/JCM.01515-06. Epub 2007 Mar 21. J Clin Microbiol. 2007. PMID: 17376882 Free PMC article.
-
Post-transplantation primary central nervous system lymphoma: A case report and review of the literature.Surg Neurol Int. 2011;2:130. doi: 10.4103/2152-7806.85471. Epub 2011 Sep 27. Surg Neurol Int. 2011. PMID: 22059125 Free PMC article.
-
Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation.Blood. 2012 Mar 15;119(11):2644-56. doi: 10.1182/blood-2011-08-371971. Epub 2011 Dec 2. Blood. 2012. PMID: 22138512 Free PMC article.
-
Colonic EBV-Associated Lymphoproliferative Disorder in a Patient Treated with Rabbit Antithymocyte Globulin for Aplastic Anemia.Case Rep Gastrointest Med. 2012;2012:395801. doi: 10.1155/2012/395801. Epub 2012 Sep 23. Case Rep Gastrointest Med. 2012. PMID: 23050175 Free PMC article.
References
-
- Chiang, K. Y., L. J. Hazlett, K. T. Godder, S. H. Abhyankar, et al. 2001. Epstein-Barr virus-associated B cell lymphoproliferative disorder following mismatched related T cell-depleted bone marrow transplantation. Bone Marrow Transplant. 28:1117-1123. - PubMed
-
- Choquet, S., B. M. Mamzer, O. Hermine, et al. 2002. Identification of prognostic factors in post-transplant lymphoproliferative disorders. Recent Results Cancer Res. 159:67-80. - PubMed
-
- Cohen, J. I. 2000. Epstein-Barr virus infection. New Engl. J. Med. 343:481-492. - PubMed
-
- Dazzi, F., and J. M. Goldman. 1998. Adoptive immunotherapy following allogeneic bone marrow transplantation. Annu. Rev. Med. 49:329-340. - PubMed
-
- Hauke, R. J., T. C. Greiner, B. N. Smir, et al. 1998. Epstein-Barr virus-associated lymphoproliferative disorder after autologous bone marrow transplantation: report of two cases. Bone Marrow Transplant. 21:1271-1274. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical